Clinical trial
A Phase I/II Study of CPI-613 in Combination With Induction/Consolidation in Older AML Patients
NCT02472626 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of CPI-613 in Combination With Induction/Consolidation in Older AML Patients
- Lead sponsor
- Wake Forest University Health Sciences
- Phase
- Phase 1/2
- Overall status
- Withdrawn
- Start date
- December 31, 2015
- Completion date
- July 31, 2016
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
untreated adult acute myeloid leukemia